/LIVN
LIVN Stock - LivaNova PLC
Healthcare|Medical - DevicesNASDAQ
$62.82+1.19%
+$0.74 (+1.19%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).75
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+12.6%upside
Target: $70.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LIVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$62.19 – $63.45
TARGET (TP)$70.75
STOP LOSS$57.79
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.02
52W High$65.57
52W Low$32.48
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.25B | $1.15B | $1.02B | $1.04B | $934.24M |
| Gross Profit | $870.87M | $771.25M | $707.23M | $705.99M | $594.76M |
| Gross Margin | 69.5% | 66.9% | 69.2% | 68.2% | 63.7% |
| Operating Income | $129.05M | $-68,498,000 | $-76,752,000 | $-784,000 | $-273,899,000 |
| Net Income | $63.23M | $17.55M | $-86,246,000 | $-135,818,000 | $-348,819,000 |
| Net Margin | 5.0% | 1.5% | -8.4% | -13.1% | -37.3% |
| EPS | $1.17 | $0.33 | $-1.61 | $-2.68 | $-7.06 |
Company Overview
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
55%
Hold / Neutral
5
45%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish5 Neutral/Bearish
Price Targets
$65
Average Target
↑ 2.7% Upside
Now
$48
Low
$65
Average
$95
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | KeyBanc Capital Markets | Initiation | Overweight | $81 |
| October 1st 2025 | Goldman | Downgrade | Neutral | $55 |
| May 20th 2025 | Wolfe Research | Upgrade | Outperform | $60 |
| February 26th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| October 4th 2024 | Goldman | Initiation | Buy | $65 |
| September 17th 2024 | Robert W. Baird | Upgrade | Outperform | $66← $55 |
| March 20th 2024 | Needham | Reiterated | Buy | - |
| February 20th 2024 | Mizuho | Upgrade | Buy | $70← $60 |
| September 6th 2023 | HSBC Securities | Initiation | Hold | $52 |
| July 19th 2023 | Robert W. Baird | Initiation | Neutral | $56 |
| April 14th 2023 | Mizuho | Initiation | Neutral | $48 |
| December 21st 2022 | Barclays | Initiation | Equal Weight | $62 |
| April 6th 2022 | Wolfe Research | Initiation | Outperform | $95 |
Earnings History & Surprises
LIVNBeat Rate
94%
Last 18 quarters
Avg Surprise
+20.9%
EPS vs Estimate
Beats / Misses
17/1
Last 12 quarters
Latest EPS
$1.11
Q4 2025
EPS Surprise History
Q1 24
+10.1%
$0.87vs$0.79
Q2 24
+62.2%
$0.73vs$0.45
Q3 24
+17.7%
$0.93vs$0.79
Q4 24
+26.8%
$0.90vs$0.71
Q1 25
+1.3%
$0.81vs$0.80
Q2 25
+17.3%
$0.88vs$0.75
Q3 25
+25.0%
$1.05vs$0.84
Q4 25
+20.8%
$1.11vs$0.92
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.81 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.92 | $1.11 | +20.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.84 | $1.05 | +25.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.75 | $0.88 | +17.3% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.80 | $0.81 | +1.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.71 | $0.90 | +26.8% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.79 | $0.93 | +17.7% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.45 | $0.73 | +62.2% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $0.79 | $0.87 | +10.1% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.62 | $0.73 | +17.7% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.58 | $0.78 | +34.5% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.41 | $0.43 | +4.9% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $0.72 | $0.81 | +12.5% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.57 | $0.58 | +1.8% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.51 | $0.53 | +3.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $0.52 | $0.48 | -7.7% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $0.50 | $0.57 | +14.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.45 | $0.68 | +51.1% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.32 | $0.52 | +62.5% | ✓ BEAT |
Latest News
Keybanc Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $81
📈 PositiveBenzinga•Dec 19, 2025, 12:02 PM
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $72
📈 PositiveBenzinga•Dec 17, 2025, 01:07 PM
LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy
📈 PositiveBenzinga•Dec 3, 2025, 02:03 PM
LivaNova Announces US Centers for Medicare & Medicaid Services Assigned VNS Therapy New Technology Ambulatory Payment Classification 1580
📈 PositiveBenzinga•Nov 24, 2025, 02:01 PM
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $70
📈 PositiveBenzinga•Nov 13, 2025, 12:38 PM
Baird Maintains Outperform on LivaNova, Raises Price Target to $70
📈 PositiveBenzinga•Nov 13, 2025, 12:36 PM
LivaNova Announces 2030 Financial Targets, Sees High-Single-Digit-Plus Revenue CAGR; Adjusted Annual Operating Margin Above 20% Over The Next 3-Years, Targeting High Twenties By 2030; EPS CAGR In The Low Double Digits To Mid-Teens; Adjusted Free Cash Flow Conversion Above 80%
📈 PositiveBenzinga•Nov 12, 2025, 08:30 PM
LivaNova Raised FY25 Adjusted Free Cash Flow Range By $20M At Midpoint To $160M-$180M (Prior View: $140M-$160M)
📈 PositiveBenzinga•Nov 5, 2025, 11:06 AM
LivaNova Raises FY2025 Adj EPS Guidance from $3.70-$3.80 to $3.80-$3.90 vs $3.75 Est, Company Now Expects FY25 Revenue To Grow Between 8.5%-9.5% (Versus 8%-9% Prior)
📈 PositiveBenzinga•Nov 5, 2025, 11:03 AM
LivaNova Q3 Adj. EPS $1.11 Beats $0.92 Estimate, Sales $357.800M Beat $343.505M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 11:00 AM
Needham Reiterates Buy on LivaNova, Maintains $64 Price Target
📈 PositiveBenzinga•Sep 3, 2025, 11:58 AM
Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $58
➖ NeutralBenzinga•Aug 21, 2025, 02:45 PM•Also:
Frequently Asked Questions about LIVN
What is LIVN's current stock price?
LivaNova PLC (LIVN) is currently trading at $62.82 per share. The stock has moved +1.19% today.
What is the analyst price target for LIVN?
The average analyst price target for LIVN is $70.75, based on 1 analyst.
What sector is LivaNova PLC in?
LivaNova PLC operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is LIVN's market cap?
LivaNova PLC has a market capitalization of $3.43 billion, making it a mid-cap company.
Does LIVN pay dividends?
No, LivaNova PLC does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATEC
Alphatec Holdings, Inc.
$20.01
Mkt Cap: $3.0B
CDTX
Cidara Therapeutics, Inc.
$220.80
Mkt Cap: $5.6B
HTFL
Heartflow, Inc. Common Stock
$30.51
Mkt Cap: $2.6B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
PBH
Prestige Consumer Healthcare Inc.
$61.74
Mkt Cap: $3.1B
SGRY
Surgery Partners, Inc.
$15.70
Mkt Cap: $2.0B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to LIVN for comparison